OKYO OKYO Pharma Ltd IFRS Annual reports only
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1849296
Financial factors as of 2025-03-31 (FY2025), by fiscal year; growth vs the previous fiscal year
Growth
Margins
Returns
Leverage & solvency
Cash quality & payout
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY2025*2025-03-31 | FY2024*2024-03-31 | FY2023*2023-03-31 | FY2022*2022-03-31 | FY2021*2021-03-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | — | — | — | — | — |
| R&D expense | $2.25M | $8.24M | $6.34M | $1.61M | $348,347 |
| Interest expense | $878,174 | $1.05M | $96,687 | — | $1,123 |
| Pretax income | -$7.97M | -$16.80M | -$13.28M | -$6.22M | -$3.38M |
| Income tax | $3.26M | -$22,416 | $12,202 | $786,521 | $24,994 |
| Net income | -$4.71M | -$16.83M | -$13.27M | -$5.43M | -$3.35M |
| EPS (basic) | -0.20 | -0.57 | -0.61 | -0.36 | -0.32 |
| EPS (diluted) | -0.20 | -0.57 | -0.61 | -0.36 | -0.32 |
| Balance sheet | |||||
| Cash & equivalents | $1.56M | $826,848 | $4.05M | $2.70M | $6.89M |
| Receivables | — | — | $592,195 | $812,956 | $43,370 |
| Current assets | $3.68M | $1.54M | $5.20M | $4.30M | $6.99M |
| PP&E, netmay include right-of-use assets (IFRS) | $2,035 | $3,350 | $7,216 | $5,225 | $6,057 |
| Total assets | $3.68M | $1.54M | $5.20M | $4.30M | $7.09M |
| Current liabilities | $9.23M | $7.42M | $7.26M | $1.35M | $1.71M |
| Short-term debt | $2.70M | — | — | — | — |
| Total liabilities | $9.23M | $7.42M | $7.26M | $1.35M | $1.77M |
| Shareholders' equity | -$5.55M | -$5.88M | -$2.05M | $2.95M | $5.32M |
| Cash flow statement | |||||
| Operating cash flow | -$1.81M | -$9.49M | -$7.70M | -$5.47M | -$1.60M |
| Capital expenditure | $1,208 | — | $5,916 | $1,669 | $6,943 |
| Free cash flow | -$1.81M | — | -$7.70M | -$5.47M | -$1.61M |
| Investing cash flow | -$1,208 | — | -$5,916 | -$1,669 | -$18,114 |
| Financing cash flow | $2.66M | $6.21M | $9.32M | $2.15M | $7.83M |
| Depreciation & amortization | $2,563 | $3,866 | $3,797 | $2,423 | $1,512 |
| Stock-based compensation | $734,989 | $1.12M | $1.29M | $1.74M | $550,138 |
Free plan shows the latest 5 periods; Pro shows all 6 🔒
· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.
· This company files only annual reports with the SEC (20-F for foreign issuers), so there is no quarterly data; factors are by fiscal year and growth is vs the previous fiscal year.
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.